Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics' stock price has been influenced by positive clinical trial results from the NAVIGATE trial, which showed efficacy in reducing liver stiffness and clinical progression. The company reported reduced net losses for Q2 and Q3 2025 and secured a $10 million credit line to fund operations through June 2026. There has been significant insider selling, and while H.C. Wainwright reiterated a "buy" rating, the company has a consensus rating of "Hold". As of November 21, 2025, the share price was $5.35, representing a 97.42% increase from November 25, 2024.

Galectin Therapeutics, as a clinical-stage biopharmaceutical company, does not experience traditional product demand seasonality. Any observed seasonality relates to stock market trends or investor behavior around reporting periods or scientific conferences. Buying GALT stock in February has the highest probability of a positive return, while December has the lowest.

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer, targeting galectin proteins. Their lead product candidate, belapectin, is in Phase 2 and Phase 3 clinical trials for MASH cirrhosis and liver fibrosis. The company is also exploring belapectin's potential in oncology and has a joint venture, Galectin Sciences, LLC, focused on developing oral galectin-3 inhibitors.

Galectin Therapeutics Inc. is headquartered in Norcross, Georgia, and maintains a laboratory in Natick, Massachusetts, collaborating with the Complex Carbohydrate Research Center at the University of Georgia. Clinical trials are conducted across the United States and at select international sites.

Galectin Therapeutics' brand reputation has been shaped by the positive outcomes of its clinical trials for belapectin in MASH cirrhosis. Encouraging data from the NAVIGATE trial presented at medical conferences has strengthened the clinical profile of belapectin. Securing a new credit line indicates continued financial backing, bolstering confidence in the company's stability.

Galectin Therapeutics Inc. has a mixed ownership structure including individual investors, institutional owners, and insiders. Individual investors hold 53% of shares, while institutional owners, including Vanguard Group Inc. and BlackRock, Inc., hold approximately 16.05%. Insiders own approximately 28.72% of the stock, with key individual owners including 10x Fund LP, James C. Czirr, Rod D. Martin, and Richard Uihlein.